Skin toxicities of targeted therapies.
Segaert
Siegfried
S
Department of Dermatology, University Hospital Gasthuisberg, Leuven, Belgium.
Chiritescu
Gabriela
G
Lemmens
Liesbeth
L
Dumon
Kristien
K
Van Cutsem
Eric
E
Tejpar
Sabine
S
D000970:Antineoplastic Agents / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D018450:Disease Progression; D018572:Disease-Free Survival; D003875:Drug Eruptions / Q000145:classification / Q000209:etiology* / Q000628:therapy; D004791:Enzyme Inhibitors / Q000009:adverse effects; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D010770:Phosphotransferases / Q000037:antagonists & inhibitors; D013684:Telangiectasis / Q000139:chemically induced; D009626:Terminology as Topic; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D010770:Phosphotransferases; D066246:ErbB Receptors